These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38462072)

  • 21. Analysis of the adverse events of Aristada：A real-world study based on FAERS database.
    Ou M; Zhou Q; Zhu H; Du Z; Shen Y; Luan P; Jiang Y
    Asian J Psychiatr; 2024 Apr; 94():103968. PubMed ID: 38354623
    [No Abstract]   [Full Text] [Related]  

  • 22. A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System.
    Tang L; Ding C; Li H; Zhou X; Yin G
    Ann Pharmacother; 2024 Apr; 58(4):375-382. PubMed ID: 37522435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
    Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
    Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS).
    Ni J; Tang X; Chen L
    BMC Pharmacol Toxicol; 2023 Aug; 24(1):41. PubMed ID: 37542326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.
    Zhou Q; Du Z; Qu K; Shen Y; Jiang Y; Zhu H; Zhang X
    Asian J Psychiatr; 2023 Dec; 90():103828. PubMed ID: 37949044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.
    Dhodapkar MM; Shi X; Ramachandran R; Chen EM; Wallach JD; Ross JS
    BMJ; 2022 Oct; 379():e071752. PubMed ID: 36198428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
    Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
    Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rising cases of drug-induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000-2022.
    McCall KL; Hennig KR; Abe ZT; Dattler DN; Hurd KL; Portnoy SL; Zagoria ZJ
    Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5797. PubMed ID: 38680101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database].
    Liu X; Chen L; Zhao L
    Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):830-836. PubMed ID: 34638200
    [No Abstract]   [Full Text] [Related]  

  • 36. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing Different Adverse Effects Among Multiple Drugs Using FAERS Data.
    Huang J; Zhang X; Du J; Duan R; Yang L; Moore JH; Chen Y; Tao C
    Stud Health Technol Inform; 2017; 245():1268. PubMed ID: 29295353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System.
    Zhang M; Li H; Huang L; Liu Y; Jiao XF; Zeng L; Jia ZJ; Cheng G; Zhang L; Zhang W
    Eur J Pediatr; 2023 Oct; 182(10):4655-4661. PubMed ID: 37561197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System.
    Raschi E; Fusaroli M; Massari F; Mollica V; Repaci A; Ardizzoni A; Poluzzi E; Pagotto U; Di Dalmazi G
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3107-e3114. PubMed ID: 35704533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.